

L Number	Hits	Search Text	DB	Time stamp
1	127	zinc adj4 metalloprotease	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/30 12:04
7	708	matrix adj4 metalloprotease	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/30 12:04
13	67	human adj4 metalloprotease	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/30 12:05
19	10	(zinc adj4 metalloprotease) and (matrix adj4 metalloprotease) and (human adj4 metalloprotease)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/07/30 12:05

	U	1	Document ID	Issue Date	Title
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6399371 B1	20020604	Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6395889 B1	20020528	Nucleic acid molecules encoding human protease homologs
3	<input type="checkbox"/>	<input type="checkbox"/>	US 6294368 B1	20010925	Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
4	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6197770 B1	20010306	Alkenyl- and alkynyl-containing metalloprotease inhibitors
5	<input type="checkbox"/>	<input type="checkbox"/>	US 6344352 B1	20020205	Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
6	<input type="checkbox"/>	<input type="checkbox"/>	US 20020072517 A1	20020613	Substituted cyclic amine metalloprotease inhibitors
7	<input type="checkbox"/>	<input type="checkbox"/>	US 20020061877 A1	20020523	Substituted cyclic amine metalloprotease inhibitors

	Current OR	Current XRef	Retrieval Classif	Inventor	Pages
1	435/325	435/219; 435/226; 435/252.33; 435/320.1; 536/23.1; 536/23.2; 536/23.5		Falduto, Michael T. et al.	72
2	536/23.2	435/252.3; 435/320.1; 435/69.1; 536/23.5		Robison, Keith E.	66
3	435/219	435/320.1; 435/69.1; 536/23.2; 536/23.5		Merkulov, Gennady V. et al.	57
4	514/238.2	534/847; 544/159; 544/383; 544/389; 544/391; 544/394; 544/406; 546/276.4; 546/335; 548/141; 548/144; 548/163; 548/233; 548/492; 548/540; 548/575; 549/444; 562/430		Natchus, Michael George et al.	57
5	435/219	435/212; 435/226		Merkulov, Gennady V. et al.	53
6	514/217.1	514/330; 514/423; 540/604; 546/225; 548/530		Natchus, Michael George et al.	40
7	514/217.11	514/330; 514/423; 540/604; 546/225; 548/530		Natchus, Michael George et al.	38

	S	C	P	2	3	4	5	Image Doc. Displayed	PT
1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6399371	<input type="checkbox"/>
2	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6395889	<input type="checkbox"/>
3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6294368	<input type="checkbox"/>
4	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6197770	<input type="checkbox"/>
5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6344352	<input type="checkbox"/>
6	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 20020072517	<input type="checkbox"/>
7	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 20020061877	<input type="checkbox"/>

	U	1	Document ID	Issue Date	Title
8	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6417219 B1	20020709	Hetero-substituted cyclic amine metalloprotease inhibitors
9	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6255064 B1	20010703	Disintegrin metalloprotease and its use

	Current OR	Current XRef	Retrieval Classif	Inventor	Pages
8	514/423	514/227.5; 514/235.2; 514/254.01; 514/274; 514/326; 514/343; 514/367; 514/378; 514/389; 514/397; 514/406; 544/141; 544/242; 544/372; 544/60; 546/208; 546/276.4; 548/171; 548/247; 548/314.7; 548/364.1; 548/537		Natchus, Michael George et al.	35
9	435/23	435/219; 435/226		Tindal, Michael Howard et al.	26

	S	C	P	2	3	4	5	Image Doc. Displayed	PT
8	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6417219	<input type="checkbox"/>
9	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6255064	<input type="checkbox"/>

	U	1	Document ID	Issue Date	Title
10	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6329418 B1	20011211	Substituted pyrrolidine hydroxamate metalloprotease inhibitors



	Current OR	Current XRef	Retrieval Classif	Inventor	Pages
10	514/423	514/228.8; 514/235.5; 514/252.06; 514/252.19; 514/256; 514/269; 514/315; 514/336; 514/365; 514/374; 514/383; 514/385; 544/106; 544/238; 544/309; 544/330; 544/358; 544/96; 546/184; 546/281.4; 548/183; 548/230; 548/262.2; 548/314.7; 548/367.4; 548/517; 548/518; 548/519; 548/533; 548/537		Cheng, Menyan et al.	23

	S	C	P	2	3	4	5	Image Doc. Displayed	PT
10	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 6329418	<input type="checkbox"/>

7/30/02

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web  
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates  
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency  
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
NEWS 6 Mar 08 Gene Names now available in BIOSIS  
NEWS 7 Mar 22 TOXLIT no longer available  
NEWS 8 Mar 22 TRCTHERMO no longer available  
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/Caplus and USPATFULL  
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY  
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.  
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 14 Apr 09 ZDB will be removed from STN  
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUIDB  
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 19 Jun 03 New e-mail delivery for search results now available  
NEWS 20 Jun 10 MEDLINE Reload  
NEWS 21 Jun 10 PCTFULL has been reloaded  
NEWS 22 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 23 Jul 19 NTIS to be reloaded July 28, 2002  
NEWS 24 Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid  
NEWS 25 Jul 29 Enhanced polymer searching in REGISTRY  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:14:07 ON 30 JUL 2002

=> File health medicine meetings pharmacology research toxicology

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'ADISALERTS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'AQUASCI' ENTERED AT 12:14:14 ON 30 JUL 2002

(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'CAPLUS' ENTERED AT 12:14:14 ON 30 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CHEMLIST' ENTERED AT 12:14:14 ON 30 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:14:14 ON 30 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CSNB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'EMBAL' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'ENERGY' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (c) 2002 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'ESBIOBASE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'FOMAD' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'HEALSAFE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'HSDB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 NATIONAL LIBRARY OF MEDICINE

FILE 'IFIPAT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (c) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'MSDS-CCOHS' ENTERED AT 12:14:14 ON 30 JUL 2002  
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NIOSHTIC' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NLDB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'NTIS' ENTERED AT 12:14:14 ON 30 JUL 2002  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2002)

FILE 'PASCAL' ENTERED AT 12:14:14 ON 30 JUL 2002  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'POLLUAB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PROMT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RTECS' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE 'SCISEARCH' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 12:14:14 ON 30 JUL 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:14:14 ON 30 JUL 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'PHIC' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'IMOBILITY' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Society of Automotive Engineers, Inc.

FILE 'AGRICOLA' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'COMPENDEX' ENTERED AT 12:14:14 ON 30 JUL 2002  
Compendex Compilation and Indexing (C) 2002  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EVENTLINE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 ELSEVIER Publishing Group, Amsterdam

FILE 'IMSDRUGCONF' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd.

FILE 'ISMEC' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'OCEAN' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PAPERCHEM2' ENTERED AT 12:14:14 ON 30 JUL 2002  
Paperchem2 compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 FOI Services, Inc. (FOI)

FILE 'DRUGUPDATES' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'INVESTEXT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'PHAR' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SYNTHLINE' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Prous Science

FILE 'USAN' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Bundesministerium fuer Bildung,  
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'CABA' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'FSTA' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 International Food Information Service

FILE 'ULIDAT' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'VETB' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:14:14 ON 30 JUL 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

```
=> s zinc (4A) metalloprotease
    33 FILES SEARCHED...
    76 FILES SEARCHED...
L1      3253 ZINC (4A) METALLOPROTEASE
```

```
=> human (4A) metalloprotease
HUMAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s human (4a) metalloprotease
    11 FILES SEARCHED...
    30 FILES SEARCHED...
    45 FILES SEARCHED...
    57 FILES SEARCHED...
```



L2 1745 HUMAN (4A) METALLOPROTEASE

=> s matrix (4a) metalloprotease

37 FILES SEARCHED...

79 FILES SEARCHED...

L3 5475 MATRIX (4A) METALLOPROTEASE

=> s l1 and l2 and l3

55 FILES SEARCHED...

L4 29 L1 AND L2 AND L3

=> duplicate

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove

ENTER L# LIST OR (END):l4

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, CHEMLIST, FEDRIP, FOREGE, HSDB, KOSMET, MEDICONF, MSDS-CCOHS, MSDS-OHS, RTECS, DGENE, DRUGLAUNCH, DRUGMONOG2, CONF, EVENTLINE, IMSDRUGCONF, DIOGENES, DRUGUPDATES, INVESTEXT, PHAR, SYNTHLINE, USAN, FORIS, FORKAT, UFORDAT'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

DUPLICATE PREFERENCE IS 'USPATFULL, DGENE'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L4

L5 29 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d l5 1-29 bib ab

L5 ANSWER 1 OF 29 USPATFULL

AN 2002:186083 USPATFULL

TI Inhibition of invasive remodelling

IN Lund, Leif Røge, Copenhagen, DENMARK

Dano, Keld, Charlottenlund, DENMARK

Stephens, Ross, Charlottenlund, DENMARK

Brunner, Nils, Hellerup, DENMARK

Solberg, Helene, Hillerød, DENMARK

Holst-Hansen, Claus, Frederiksberg C, DENMARK

Nielsen, John Romer, Copenhagen O, DENMARK

PI US 2002099004 A1 20020725

AI US 2001-995636 A1 20011129 (9)

RLI Continuation of Ser. No. US 1999-319464, filed on 27 Aug 1999, ABANDONED  
A 371 of International Ser. No. WO 1997-DK555, filed on 8 Dec 1997,  
UNKNOWN

PRAI DK 1996-1402 19961206

DT Utility

FS APPLICATION

LREP BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC,  
20001

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 2781

AB Invasive remodelling in a mammal may be inhibited by (1) inhibiting or  
abolishing the protein cleaving action of plasmin and (2) inhibiting or  
abolishing the protein cleaving action of at least one additional  
proteolytic enzyme active in invasive remodelling, such as a  
metalloprotease.

L5 ANSWER 2 OF 29 USPATFULL

AN 2002:141530 USPATFULL

TI Substituted cyclic amine metalloprotease inhibitors

IN Natchus, Michael George, Glendale, OH, UNITED STATES

De, Biswanath, Cincinnati, OH, UNITED STATES

Pikul, Stanislaw, Mason, OH, UNITED STATES

Almstead, Neil Gregory, Loveland, OH, UNITED STATES  
Bookland, Roger Gunnard, Cincinnati, OH, UNITED STATES  
Taiwo, Yetunde Olabisi, West Chester, OH, UNITED STATES  
Cheng, Menyan, West Chester, OH, UNITED STATES  
PA The Procter & Gamble Company (U.S. corporation)  
PI US 2002072517 A1 20020613  
AI US 2001-888759 A1 20010625 (9)  
RLI Division of Ser. No. US 1997-918317, filed on 26 Aug 1997, PENDING  
PRAI US 1996-24842P 19960828 (60)  
DT Utility  
FS APPLICATION  
LREP Tanaga A. Boozer, The Procter & Gamble Company, Health Care Research  
Center (Box 1050), P.O. Box 8006, Mason, OH, 45040-8006  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 3 OF 29 USPATFULL  
AN 2002:141093 USPATFULL  
TI Methods for identifying a protease inhibitor  
IN Chadwick, Mark P., Cambridge, UNITED KINGDOM  
Russell, Stephen J., Rochester, MN, UNITED STATES  
PI US 2002072075 A1 20020613  
AI US 2001-791426 A1 20010223 (9)  
PRAI US 2000-185203P 20000225 (60)  
DT Utility  
FS APPLICATION  
LREP Kathleen M. Williams, Ph.D., Palmer & Dodge, LLP, 111 Huntington Avenue  
At The Prudential Center, Boston, MA, 02199-7613  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are disclosed whereby inhibition of proteolytic activity causes an increase in delivery of a transferable label from a viral display package to a target cell. Assaying for the transferable label in the target cell in the presence of a test substance can identify the test substance as a protease inhibitor. Protease inhibitors so identified are used therapeutically, to treat conditions such as cancer, inflammation, rheumatoid arthritis and other autoimmune diseases, and infections, including AIDS, herpes, and hepatitis.

L5 ANSWER 4 OF 29 USPATFULL  
AN 2002:119889 USPATFULL  
TI Substituted cyclic amine metalloprotease inhibitors  
IN Natchus, Michael George, Glendale, OH, UNITED STATES  
De, Biswanath, Cincinnati, OH, UNITED STATES  
Pikul, Stanislaw, Mason, OH, UNITED STATES  
Almstead, Neil Gregory, Loveland, OH, UNITED STATES  
Bookland, Roger Gunnard, Cincinnati, OH, UNITED STATES

Taiwo, Yetunde Olabisi, West Chester, OH, UNITED STATES  
Cheng, Menyan, West Chester, OH, UNITED STATES  
PA The Procter & Gamble Company (U.S. corporation)  
PI US 2002061877 A1 20020523  
AI US 2001-888675 A1 20010625 (9)  
RLI Division of Ser. No. US 1997-918317, filed on 26 Aug 1997, PENDING  
PRAI US 1996-24842P 19960828 (60)  
DT Utility  
FS APPLICATION  
LREP Tanaga A. Boozer, The Procter & Gamble Company, Health Care Research  
Center (Box 1050), P.O. Box 8006, Mason, OH, 45040-8006  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 5 OF 29 USPATFULL  
AN 2002:168251 USPATFULL  
TI Hetero-substituted cyclic amine metalloprotease inhibitors  
IN Natchus, Michael George, Glendale, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Pikul, Stanislaw, Mason, OH, United States  
Almstead, Neil Gregory, Loveland, OH, United States  
Bookland, Roger Gunnard, Cincinnati, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
Cheng, Menyan, West Chester, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 6417219 B1 20020709  
AI US 1997-918317 19970826 (8)  
PRAI US 1996-24842P 19960828 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Stockton, Laura L.  
LREP Roof, Carl J., Boozer, Tanaga A.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 6 OF 29 USPATFULL  
AN 2002:129957 USPATFULL

TI Diheterocyclic metalloprotease inhibitors  
IN Pikul, Stanislaw, Mason, OH, United States  
Almstead, Neil Gregory, Loveland, OH, United States  
Bradley, Rimma Sandler, Fairfield, OH, United States  
McDow-Dunham, Kelly Lynn, Loveland, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Natchus, Michael George, Glendale, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
Cupps, Thomas Lee, Oxford, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 6399598 B1 20020604  
AI US 2000-516726 20000301 (9)  
RLI Division of Ser. No. US 1997-918957, filed on 26 Aug 1997, now patented,  
Pat. No. US 6121258  
PRAI US 1996-24846P 19960828 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Coleman, Brenda  
LREP Roof, Carl J., Boozer, Tanaga A., Clark, Karen F.  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2013  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides compounds of formula ##STR1##

as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 7 OF 29 USPATFULL  
AN 2002:122764 USPATFULL  
TI Nucleic acid molecules encoding human protease homologs  
IN Robison, Keith E., Wilmington, MA, United States  
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.  
corporation)  
PI US 6395889 B1 20020528  
AI US 1999-392184 19990909 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore,  
William W.  
LREP Alston & Bird LLP  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 5266  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to polynucleotides encoding newly identified protease homologs. The invention also relates to the proteases. The invention further relates to methods using the protease polypeptides and polynucleotides as a target for diagnosis and treatment in protease-mediated disorders. The invention further relates to drug-screening methods using the protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protease polypeptides and polynucleotides. The invention

further relates to procedures for producing the protease polypeptides and polynucleotides.

L5 ANSWER 8 OF 29 USPATFULL  
AN 2002:24192 USPATFULL  
TI Isolated **human metalloprotease** proteins, nucleic acid molecules encoding human protease proteins, and uses thereof  
IN Merkulov, Gennady V., Baltimore, MD, United States  
Ye, Jane, Boyds, MD, United States  
Di Francesco, Valentina, Rockville, MD, United States  
Beasley, Ellen M., Darnestown, MD, United States  
PA PE Corporation, Norwalk, CT, United States (U.S. corporation)  
PI US 6344352 B1 20020205  
AI US 2001-920048 20010802 (9)  
RLI Division of Ser. No. US 2001-813819, filed on 22 Mar 2001, now patented, Pat. No. US 6294368  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Fronda, Christian L  
LREP Celera Genomics, Millman, Robert A., Sun-Hoffman, Lin  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 2909

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

L5 ANSWER 9 OF 29 USPATFULL  
AN 2001:226672 USPATFULL  
TI Substituted pyrrolidine hydroxamate metalloprotease inhibitors  
IN Cheng, Menyan, West Chester, OH, United States  
Natchus, Michael George, Glendale, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Almstead, Neil Gregory, Loveland, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
Pikul, Stanislaw, Mason, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 6329418 B1 20011211  
AI US 1999-274564 19990323 (9)  
PRAI US 1998-81667P 19980414 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Balasubramanian, Venkataraman  
LREP Roof, Carl J., Kellerman, James C., Boozer, Tanaga A.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1926

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are potent inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to compounds having a structure according to the following Formula (I): ##STR1##

wherein R.sub.1, R.sub.2, X, Z, m, and n are defined below.

to This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of diseases and conditions which are characterized by unwanted metalloprotease activity. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for metalloprotease-related maladies using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 10 OF 29 USPATFULL

AN 2001:185528 USPATFULL

TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use

IN Campbell, David A., 1492 Ascension Dr., San Mateo, CA, United States 94402

Patel, Dinesh V., 45109 Cougar Cir., Fremont, CA, United States 94086

Xiao, Xiao-Yi, 11025 N. Torrey Pines Rd., #100, La Jolla, CA, United States 92037

PI US 6307101 B1 20011023

AI US 1999-271801 19990317 (9)

RLI Continuation of Ser. No. US 1998-81466, filed on 19 May 1998, now patented, Pat. No. US 5929278 Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner: Delacroix-Muirheid, C.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 11 OF 29 USPATFULL

AN 2001:163038 USPATFULL

TI Isolated **human metalloprotease** proteins, nucleic acid molecules encoding human protease proteins, and uses thereof

IN Merkulov, Gennady V., Baltimore, MD, United States

Ye, Jane, Boyds, MD, United States

Di Francesco, Valentina, Rockville, MD, United States

Beasley, Ellen M., Darnestown, MD, United States

PA Applera Corporation, Norwalk, CT, United States (U.S. corporation)

PI US 6294368 B1 20010925

AI US 2001-813819 20010322 (9)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Fronda,  
Christian L.  
LREP Genomics, Celera, Millman, Robert A., Sun-Hoffman, Lin  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 2334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

L5 ANSWER 12 OF 29 USPATFULL

AN 2001:102574 USPATFULL

TI Disintegrin metalloprotease and its use

IN Tindal, Michael Howard, Wyoming, OH, United States

Haqqi, Tariq Mehmood, Cleveland Heights, OH, United States

PA The Procter & Gamble Company, Mason, OH, United States (U.S.  
corporation)

Case Western Reserve University, Cleveland, OH, United States (U.S.  
corporation)

PI US 6255064 B1 20010703

AI US 1998-30335 19980225 (9)

RLI Continuation-in-part of Ser. No. WO 1997-US3217, filed on 28 Feb 1997  
Continuation-in-part of Ser. No. US 1997-810153, filed on 25 Feb 1997,  
now abandoned

PRAI US 1996-12679P 19960301 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Slobodyansky, Elizabeth

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proteins comprising the amino acid sequence of human disintegrin and DNA sequences encoding the human disintegrin protein are identified. Also described are methods for determining the activity of the disintegrin and for identifying compounds capable of binding to and inhibiting the disintegrin protein. Recombinant expression vectors comprising the DNA sequences encoding the disintegrin, host cells comprising the recombinant expression vector, and antibodies to the disintegrin protein and screening methods for detecting levels of disintegrin protein are exemplified.

L5 ANSWER 13 OF 29 USPATFULL

AN 2001:33267 USPATFULL

TI Alkenyl- and alkynyl-containing metalloprotease inhibitors

IN Natchus, Michael George, Glendale, OH, United States

Bookland, Roger Gunnard, Cincinnati, OH, United States

Almstead, Neil Gregory, Loveland, OH, United States

Pikul, Stanislaw, Mason, OH, United States

De, Biswanath, Cincinnati, OH, United States

Cheng, Menyan, West Chester, OH, United States

PA The Procter & Gamble Co., Cincinnati, OH, United States (U.S.  
corporation)

PI US 6197770 B1 20010306

AI US 2000-517080 20000301 (9)

PRAI US 1999-122644P 19990303 (60)

DT Utility  
FS Granted  
EXNAM Primary Examiner: Ramsuer, Robert W.  
LREP Roof, Carl J., Clark, Karen F.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4321

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): ##STR1##

where X, W, Z, A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5' and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

L5 ANSWER 14 OF 29 USPATFULL

AN 2000:125049 USPATFULL

TI Bidentate metalloprotease inhibitors

IN Almstead, Neil Gregory, Loveland, OH, United States

De, Biswanath, Cincinnati, OH, United States

Bradley, Rimma Sandler, Fairfield, OH, United States

Garrett, Garry Steven, Cincinnati, OH, United States

Marlin, II, John Emory, Bridgewater, NJ, United States

McIver, John McMillan, Cincinnati, OH, United States

Wang, Zhe, Hockessin, DE, United States

Taiwo, Yetunde Olabisi, West Chester, OH, United States

PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

PI US 6121272 20000919

AI US 1997-918318 19970826 (8)

PRAI US 1996-24746P 19960828 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Sripada, Pavanaram K

LREP Roof, Carl J., Suter, David L.

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester, acyloxyamide, or imide thereof. Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 15 OF 29 USPATFULL



AN 2000:125035 USPATFULL  
TI 1,5-heterocyclic metalloprotease inhibitors  
IN Pikul, Stanislaw, Mason, OH, United States  
Almstead, Neil Gregory, Loveland, OH, United States  
Bradley, Rimma Sandler, Fairfield, OH, United States  
McDow-Dunham, Kelly Lynn, Loveland, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Natchus, Michael George, Glendale, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
Cupps, Thomas Lee, Norwich, NY, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 6121258 20000919  
AI US 1997-918957 19970826 (8)  
PRAI US 1996-24846P 19960828 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda  
LREP Roof, Carl J., Suter, David L.  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2070

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases.

Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 16 OF 29 USPATFULL  
AN 2000:7413 USPATFULL  
TI Spirocyclic containing hydroxamic acids useful as metalloprotease inhibitors  
IN Wang, Zhe, Wilmington, DE, United States  
Almstead, Neil Gregory, Loveland, OH, United States  
Bradley, Rimma Sandler, Fairfield, OH, United States  
Natchus, Michael George, Glendale, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Pikul, Stanislaw, Mason, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 6015912 20000118  
AI US 1997-918328 19970826 (8)  
PRAI US 1996-24766P 19960828 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Higel, Floyd D.  
LREP Roof, Carl J., Suter, David L., Rasser, Jacobus C.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2616

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or

imide thereof are useful as inhibitors of metalloproteases.

Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 17 OF 29 USPATFULL  
AN 1999:151215 USPATFULL  
TI Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use  
IN Campbell, David, San Mateo, CA, United States  
Look, Gary C., Santa Clara, CA, United States  
Szardenings, Anna Katrin, Santa Clara, CA, United States  
Patel, Dinesh V., Fremont, CA, United States  
PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)  
PI US 5990112 19991123  
AI US 1996-670713 19960618 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Bernhardt, Emily  
LREP Swiss, Gerald F., Stevens, Lauren L.  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1564  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel inhibitors of metalloproteases are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.

L5 ANSWER 18 OF 29 USPATFULL  
AN 1999:85629 USPATFULL  
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use  
IN Campbell, David A., San Mateo, CA, United States  
Patel, Dinesh V., Fremont, CA, United States  
Xiao, Xiao-Yi, La Jolla, CA, United States  
PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)  
PI US 5929278 19990727  
AI US 1998-81466 19980519 (9)  
RLI Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 which is a continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.  
LREP Swiss, Gerald F., Stevens, Lauren L.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 2235  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are

useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 19 OF 29 USPATFULL  
AN 1999:43850 USPATFULL  
TI Process for preparing synthetic **matrix metalloprotease**  
inhibitors  
IN Levy, Daniel E., Alameda, CA, United States  
Grobelyny, Damian, Watsonia North, Australia  
Tang, Cho, Moraga, CA, United States  
Holme, Kevin R., Alameda, CA, United States  
Galardy, Richard E., Guilford, CT, United States  
Schultz, Gregory S., Gainesville, FL, United States  
Nematalia, Asaad, Alameda, CA, United States  
Musser, John H., San Carlos, CA, United States  
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)  
The University of Florida, Gainesville, FL, United States (U.S.  
corporation)  
PI US 5892112 19990406  
AI US 1994-184727 19940121 (8)  
RLI Continuation-in-part of Ser. No. US 1993-44324, filed on 7 Apr 1993 And  
a continuation of Ser. No. US 1992-881630, filed on 12 May 1992, now  
patented, Pat. No. US 5270326 which is a continuation of Ser. No. US  
1990-616021, filed on 20 Nov 1990, now patented, Pat. No. US 5114953 ,  
said Ser. No. US 44324 which is a continuation-in-part of Ser. No. US  
1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384  
which is a continuation of Ser. No. US 1991-747751, filed on 20 Aug  
1991, now patented, Pat. No. US 5239078 And Ser. No. US 1991-747752,  
filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a  
continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990,  
now patented, Pat. No. US 5183900 , said Ser. No. US 747751 which is a  
continuation-in-part of Ser. No. US 615798  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.  
LREP Lyon & Lyon LLP  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 3113  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Synthetic mammalian **matrix metalloprotease**  
inhibitors are disclosed that are useful for treating or preventing  
diseases wherein said diseases are caused by unwanted mammalian  
**matrix metalloprotease** activity and include skin  
disorders, keratoconus, restenosis, rheumatoid arthritis, wounds,  
cancer, angiogenesis and shock.

L5 ANSWER 20 OF 29 USPATFULL  
AN 1998:135148 USPATFULL  
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising  
same and methods of their use  
IN Campbell, David A., San Mateo, CA, United States  
Patel, Dinesh V., Fremont, CA, United States  
Xiao, Xiao-Yi, San Diego, CA, United States  
PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)  
PI US 5831004 19981103  
AI US 1995-549345 19951027 (8)  
RLI Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995,

now abandoned which is a continuation-in-part of Ser. No. US  
1994-329420, filed on 27 Oct 1994, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner:  
Delacroix-Muirheid, C.  
LREP Swiss, Gerald F., Stevens, Lauren L.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 2313

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 21 OF 29 USPATFULL  
AN 1998:135060 USPATFULL  
TI Phosphinic acid amides as **matrix metalloprotease** inhibitors  
IN Pikul, Stanislaw, Mason, OH, United States  
McDow-Dunham, Kelly Lynn, Loveland, OH, United States  
De, Biswanath, Cincinnati, OH, United States  
Taiwo, Yetunde Olabisi, West Chester, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 5830915 19981103  
AI US 1997-918950 19970826 (8)  
PRAI US 1996-24765P 19960828 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: O'Sullivan, Peter  
LREP Hake, Richard A., McMahon, Mary Pat, Suter, David L.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1864

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds which are useful as inhibitors of **matrix metalloproteases**, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described in the claims, a stereoisomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester acyloxyamide, imide or derivative thereof.

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by **matrix metalloprotease** activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 22 OF 29 USPATFULL  
AN 1998:75584 USPATFULL  
TI Synthetic **matrix metalloprotease** inhibitors and use thereof

IN Levy, Daniel E., Alameda, CA, United States  
 Grobelny, Damian, Watsonia North, Australia  
 Tang, Cho, Moraga, CA, United States  
 Holme, Kevin R., Alameda, CA, United States  
 Galardy, Richard E., Guilford, CT, United States  
 Schultz, Gregory S., Gainesville, FL, United States  
 Nematalia, Asaad, Alameda, CA, United States  
 Musser, John H., San Carlos, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)  
 The University of Florida, Gainesville, FL, United States (U.S. corporation)

PI US 5773438 19980630  
 AI US 1994-464927 19940605 (8)  
 RLI Division of Ser. No. US 1994-184727, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-44324, filed on 7 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384, issued on 7 Dec 1993 which is a continuation-in-part of Ser. No. US 1990-477751, filed on 9 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900, issued on 2 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-881630, filed on 12 May 1992, now patented, Pat. No. US 5270326, issued on 14 Dec 1993 which is a continuation of Ser. No. US 1990-616021, filed on 21 Nov 1990, now patented, Pat. No. US 5114953, issued on 19 May 1992

DT Utility  
 FS Granted  
 EXNAM Primary Examiner: McKane, Joseph  
 LREP Lyon & Lyon LLP  
 CLMN Number of Claims: 23  
 ECL Exemplary Claim: 1  
 DRWN 7 Drawing Figure(s); 5 Drawing Page(s)  
 LN.CNT 2719  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic mammalian **matrix metalloprotease** inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian **matrix metalloprotease** activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.

L5 ANSWER 23 OF 29 USPATFULL  
 AN 97:115305 USPATFULL  
 TI Inhibition of angiogenesis by synthetic **matrix metalloprotease** inhibitors

IN Galardy, Richard E., Suilford, CT, United States  
 PA Glycomed, Inc., Alameda, CA, United States (U.S. corporation)  
 PI US 5696147 19971209  
 AI US 1993-161786 19931203 (8)  
 RLI Continuation of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384 which is a continuation-in-part of Ser. No. US 1991-747751, filed on 20 Aug 1991, now patented, Pat. No. US 5239078 Ser. No. Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 And Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900

DT Utility  
 FS Granted  
 EXNAM Primary Examiner: McKane, Joseph  
 LREP Lyon & Lyon LLP  
 CLMN Number of Claims: 13  
 ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1461

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic mammalian **matrix metalloprotease** inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.

L5 ANSWER 24 OF 29 USPATFULL

AN 97:88979 USPATFULL

TI Lactam-containing hydroxamic acids

IN De, Biswanath, Cincinnati, OH, United States

Wahl, Christopher Thomas, Hamilton, OH, United States

Natchus, Michael George, Cincinnati, OH, United States

Cheng, Menyan, West Chester, OH, United States

PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

PI US 5672598 19970930

AI US 1995-407839 19950321 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Bond, Robert T.

LREP Suter, David L., Hake, Richard A., Roof, Carl J.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1,2

DRWN No Drawings

LN.CNT 1837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds that exhibit inhibitory activity against **matrix metalloproteases** ("MMPs"). Because MMPs are known to play a role in tissue degradation, the compounds of the present invention may be useful in preventing or treating diseases associated with excess MMP activity. In particular, the compounds have a structure according to Formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are various substituents as described in the specification; and Q is an alkyl chain, an alkenyl chain, a heteroalkyl chain, or a heteroalkenyl chain, wherein said chain has 2, 3, or 4 chain atoms and is unsubstituted or substituted with one or more alkyl moieties; or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, acyloxyamide, or imide thereof. Preferred are those compounds where Q is an alkyl chain having 2, 3 or 4 chain atoms.

The invention also relates to pharmaceutical compositions comprising these compounds, and methods for preventing or treating diseases associated with unwanted MMP activity using the compounds and compositions.

L5 ANSWER 25 OF 29 USPATFULL

AN 97:51993 USPATFULL

TI Hydroxamic acid-containing inhibitors of **matrix metalloproteases**

IN Yelm, Kenneth Edward, Fairfield, OH, United States

PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

PI US 5639746 19970617

AI US 1994-366062 19941229 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Conrad, Joseph

LREP Roof, Carl J., Hake, Richard A., Clark, Karen F.

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1062

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides hydroxamic acid-containing compounds which are useful as inhibitors of **matrix metalloproteases** and which are effective in treating conditions associated with excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula I ##STR1## wherein (A)R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently selected from various substituents; and

(B) where R.sup.3 and R.sup.4 or R.sup.4 and R.sup.5 may together comprise a cyclic moiety; or a pharmaceutically-acceptable salt, biohydrolyzable amide or biohydrolyzable ester thereof.

In other aspects, the invention is directed to pharmaceutical compositions containing the compounds of Formula (I), and to methods of treating diseases characterized by **matrix metalloprotease** activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 26 OF 29 USPATFULL

AN 93:102796 USPATFULL

TI Inhibition of angiogenesis by synthetic **matrix metalloprotease** inhibitors

IN Galardy, Richard E., 73 Faulkner Dr., Suilford, CT, United States 06437

PI US 5268384 19931207

AI US 1992-817039 19920107 (7)

RLI Continuation-in-part of Ser. No. US 1991-747751, filed on 20 Aug 1991, now patented, Pat. No. US 5239078 And a continuation-in-part of Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 And a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900

DT Utility

FS Granted

EXNAM Primary Examiner: Springer, David B.

LREP Cagan, Felissa H., Giotta, Gregory J.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic mammalian **matrix metalloprotease** inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.

L5 ANSWER 27 OF 29 USPATFULL

AN 93:70003 USPATFULL

TI **Matrix metalloprotease** inhibitors

IN Galardy, Richard E., Guilford, CT, United States

Grobelny, Damian, Macleod West, Australia

Musser, John H., Alameda, CA, United States

PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)

PI US 5239078 19930824

AI US 1991-747751 19910820 (7)

RLI Continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990

DT Utility

FS Granted

EXNAM Primary Examiner: Springer, David B.

LREP Murashige, Kate H., Giotta, Gregory J.

CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1125  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;

R.sup.3 is H or alkyl (1-4C);

R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;

n is 0, 1 or 2;

m is 0 or 1; and

x is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or

X is an amino acid residue or amide thereof; or

X is the residue of a cyclic amine or heterocyclic amine;

Y is selected from the group consisting of R.sup.7 ONR.sup.6 CONR.sup.6 -, R.sup.6.sub.2 NCONOR.sup.7 -, and R.sup.6 CONOR.sup.7 -, wherein each R.sup.6 is independently H or lower alkyl (1-4C); R.sup.7 is lower alkyl (1-4C) or an acyl group; and

wherein --CONR.sup.3 -- is optionally in modified isoteric form are inhibitors of **matrix metalloproteases**.

L5 ANSWER 28 OF 29 USPATFULL  
AN 93:14707 USPATFULL  
TI **Matrix metalloprotease** inhibitors  
IN Galardy, Richard E., 73 Faulkner Dr., Guilford, CT, United States 06437  
Grobelny, Damian, 10 Victoria Ave., Macleod West, 3085, Australia  
PI US 5189178 19930223  
AI US 1991-747752 19910820 (7)  
RLI Continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Springer, David B.  
LREP Murashige, Kate H., Giotta, Gregory J., Cagan, Felissa H.  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1146  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;

R.sup.3 is H or alkyl (1-4C);

R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;

n is 0, 1 or 2;



m is 0 or 1; and

X is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or

X is an amino acid residue or amide thereof; or

X is the residue of a cyclic amine or heterocyclic amine;

wherein R.sup.6 is H or lower alkyl (1-4C) and R.sup.7 is H, lower alkyl (1-4C) or an acyl group, and wherein --CONR.sup.3 -- is optionally in modified isosteric form

are useful for treating conditions which are characterized by unwanted **matrix metalloprotease** activities.

L5 ANSWER 29 OF 29 DGENE (C) 2002 THOMSON DERWENT  
AN ABB77184 Peptide DGENE  
TI New **human matrix metalloprotease** gene and  
protein, useful for diagnosing, staging, preventing or treating cancer or  
inflammatory diseases (e.g. arthritis), as well as in screening drugs for  
treating these diseases -  
IN Falduto M T; Magnuson S R; Morgan D W  
PA (FALD-I) FALDUTO M T.  
(MAGN-I) MAGNUSON S R.  
(MORG-I) MORGAN D W.  
PI US 2002031817 A1 20020314 44p  
AI US 1999-391104 19990907  
PRAI US 1997-814394 19970311  
DT Patent  
LA English  
OS 2002-361182 [39]  
AB The sequence represents the **matrix metalloprotease**  
protein **zinc** binding consensus sequence, presents in the  
putative catalytic domain. The invention relates to a novel  
polynucleotide, which comprises a nucleotide sequence encoding a  
**human matrix metalloprotease** protein  
(designated MMP-ABT). The protein of the invention has cytostatic,  
anti-inflammatory, and anti-arthritic activity. The polynucleotide may  
have a use in gene therapy. The MMP-ABT polynucleotides and proteins are  
useful for detecting, diagnosing, staging, monitoring, prognosing,  
preventing or treating cancer or inflammatory diseases (e.g. arthritis).  
The MMP-ABT proteins and polynucleotides are also useful developing  
therapeutic agents that affect MMP function.

=>

<-----User Break----->